0.2% w/v in 95% ethanol) were added to 1.2 mL of the homogenate
B.MasnecS.KraljT.PerisaM
[DOI] [PubMed] [Google Scholar] [55].Iikuni N, Loureno EV, Hahn BH
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
Next-generation Candida albicans vaccine VXV-01 containing recombinant Als3p and Hyr1p antigens for invasive Candida infections
Intrinsic factor, Medline Plus, Vitamin B12, Fact Sheet for Consumers, National Institutes of Health, Office of Dietary Supplements, Vitamin B12, Fact Sheet for Health Professionals, National Institutes of Health, Office of Dietary Supplements Pawlak R
